Highlights

  • Memphasys has signed an exclusive Felix commercialisation agreement covering Denmark, Sweden, Norway, Finland and Iceland.
  • The three-year commercial term includes minimum contracted purchases of €526,500 after a three-month evaluation period.
  • An initial order worth €20,625 will be supplied and invoiced in the September quarter, alongside three Felix systems.
  • The agreement expands Felix commercial activity to nine European countries.
  • NOVIVITAE will oversee clinic engagement, demonstrations, Training and first-line customer support across the Nordic region.

Memphasys Limited (ASX:MEM) has expanded the European commercial reach of its Felix System after entering an exclusive agreement with Denmark-based NOVIVITAE ApS covering five Nordic markets.

Memphasys shares were trading flat at AUD 0.0050 during the morning session on 1 September 2026. The latest agreement adds Denmark, Sweden, Norway, Finland and Iceland to the company’s existing commercial sales or arrangements in Italy, the United Kingdom, Türkiye and Poland.

The deal takes Felix commercial activity across nine European countries and establishes a three-year pathway for contracted purchases following an initial evaluation phase.

Nordic Agreement

Under the agreement, NOVIVITAE has been appointed Memphasys’ exclusive commercialisation partner for Felix across the five Nordic countries.

The arrangement begins immediately with an initial €20,625 order to be supplied and invoiced during the September quarter, together with three Felix systems.

A three-month evaluation period will run before the longer-term minimum purchase commitments begin.

During that period, Memphasys and NOVIVITAE will work on commercial planning, distributor preparation and market-development activities ahead of broader introduction of Felix to IVF clinics.

Following the evaluation period, the three-year commercial term includes minimum contracted purchases totalling €526,500.

The agreement also includes quarterly ordering requirements and increasing minimum purchase commitments over the term.

Exclusivity is subject to NOVIVITAE meeting agreed minimum purchasing levels and other material performance obligations.

European Footprint Broadens

The Nordic agreement expands Memphasys’ commercial presence beyond its existing European markets.

Felix already has commercial sales or agreements covering Italy, the United Kingdom, Türkiye and Poland. Adding the five Nordic countries increases the number of European markets with commercial activity to nine.

Memphasys is pursuing a combination of direct and distributor-led channels as it seeks to expand contracted sales for Felix.

The company’s commercial strategy also includes scaling production to improve margins and increasing adoption of Felix as a sperm-preparation technology within assisted reproductive treatment.

The latest agreement fits within that wider rollout by using a local distribution partner with established relationships across IVF laboratories and fertility clinics.

Nordic Fertility Market

Memphasys identified the Nordic region as an established market for assisted reproductive technology.

The company cited approximately 55,000 ART treatment cycles across Denmark, Sweden, Norway, Finland and Iceland in 2020.

Memphasys noted that the 2020 period was affected by COVID-19 and presented the figure as a historical benchmark rather than a current market forecast.

The commercial model for Felix also carries a recurring-use component.

Each Felix procedure requires a single disposable cartridge, meaning clinic adoption and higher utilisation could translate into repeat cartridge demand.

However, the company has not provided forecasts for procedure volumes, clinic adoption or Revenue beyond the minimum contracted value included in the NOVIVITAE agreement.

What Felix Does

Memphasys is an Australian reproductive biotechnology company commercialising the Felix System, a patented bio-separation technology designed for sperm selection in human assisted reproduction.

Felix combines electrophoresis with size-exclusion membranes to isolate viable sperm cells.

The company says the process is designed to offer a faster, gentler and more standardised alternative to conventional centrifugation.

Memphasys’ technology is intended to improve sperm quality while reducing laboratory processing time. Its commercial strategy centres on expanding adoption through fertility clinics and distribution partners.

The Nordic Partnership will support that strategy through local demonstrations, training and clinic engagement.

NOVIVITAE’s Role

NOVIVITAE is a Denmark-based IVF and laboratory-technology distributor serving IVF clinics and sperm and egg banks across the Nordic region.

Its responsibilities under the agreement include developing relationships with fertility specialists, IVF clinics, embryologists and key opinion leaders.

The distributor will also conduct Felix product demonstrations and training, support clinic adoption and provide first-line customer support across Denmark, Sweden, Norway, Finland and Iceland.

Memphasys highlighted NOVIVITAE’s direct engagement with IVF laboratories and embryologists as part of the rationale for the partnership.

The distributor has also participated in scientific workshops, including co-organising vitrification workshops at the Nordic IVF Laboratory Society’s 2024 meeting in Copenhagen.

Commercial Activity Ahead

Memphasys’ immediate focus will be on fulfilling the initial order and preparing the Nordic markets during the three-month evaluation period.

Near-term activities will include distributor training, market-development planning, clinic engagement and product demonstrations.

Quarterly minimum purchase commitments will begin after the evaluation period.

Non-Executive Director and Commercialisation Committee Chair Marjan Mikel said the agreement represented another step in broadening the European commercial footprint of Felix.

She said the company now has commercial arrangements across nine European countries and highlighted NOVIVITAE’s hands-on approach to introducing technology and supporting clinic adoption.

Mikel also said Memphasys has a number of advanced commercial discussions progressing elsewhere in Europe, while its Director of Commercial Operations-Europe is due to commence in mid-September.

NOVIVITAE Managing Director Søren Venderby said the distributor had seen early interest from IVF clinics in the region, particularly around Felix’s clinical characteristics and potential impact on laboratory workflow and efficiency.

What Investors May Be Watching

The Nordic agreement gives Memphasys a defined commercial structure for Felix across five additional European countries, supported by minimum contracted purchases of €526,500 over three agreement years after the evaluation period.

The first practical milestones will be delivery of the €20,625 initial order, distributor training and engagement with IVF clinics across the Nordic region.

Beyond that, attention may centre on whether clinic adoption develops sufficiently to support the quarterly minimum purchase commitments and recurring disposable-cartridge demand.

The company has also indicated that further commercial discussions are progressing across Europe, while its new Director of Commercial Operations-Europe is expected to start in mid-September.

For now, the Nordic agreement expands Felix’s European reach to nine countries while giving Memphasys another distributor-led pathway for commercial adoption.